NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021
b'NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease.
RBC Capital Markets Virtual Global Healthcare Conference Fireside Chat at 11:30 a.m. ET on May 19
Oppenheimer Rare & Orphan Disease Summit presentation on May 21
PITTSBURGH, May 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the RBC Capital Markets Virtual Global Healthcare Conference, as well as present a corporate overview and business update at the Oppenheimer Rare & Orphan Disease Summit, which are both being held in May 2021.
Conferences Details:
| Event: | RBC Capital Markets Virtual Global Healthcare Conference |
| Format: | Fireside Chat |
| Date: | Wednesday, May 19th |
| Time: | 11:30 a.m. ET |
| Location: | Webcast Link – or at the company’s website (click here) |
| Event: | Oppenheimer Rare & Orphan Disease Summit |
| Format: | Presentation |
| Date: | Friday, May 21st |
| Location: | Webcast Link – or at the company’s website (click here) |
About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.
NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
OP: (617) 430-7576
NeuBase Media Information:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
(858) 344-8091
[email protected]
